Vaccination and passive immunisation against Staphylococcus aureus.
about
Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trialsStaphylococcus aureus biofilms: properties, regulation, and roles in human diseaseVaccines for the 21st centuryThe Staphylococcus aureus peptidoglycan protects mice against the pathogen and eradicates experimentally induced infectionThe potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureusRapid Identification of Vancomycin Resistant Enterococcus Faecalis Clinical Isolates using a Sugar Fermentation Method.Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysisInhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.The potential economic value of a Staphylococcus aureus vaccine for neonatesMethicillin-Resistant Staphylococcus aureus: A Growing Risk in the Hospital and in the Community.Molecular pathogenesis of Staphylococcus aureus infectionProgress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration.Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters.Staphylococcus aureus seroproteomes discriminate ruminant isolates causing mild or severe mastitisRecombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model.Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans.Correlation between nasal microbiome composition and remote purulent skin and soft tissue infections.Protective activity of the CnaBE3 domain conserved among Staphylococcus aureus Sdr proteins.In silico analysis for identifying potential vaccine candidates against Staphylococcus aureus.Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surfaceActive Immunization with Extracellular Vesicles Derived from Staphylococcus aureus Effectively Protects against Staphylococcal Lung Infections, Mainly via Th1 Cell-Mediated ImmunityAttenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein EfbStaphylococcus aureus virulence is enhanced by secreted factors that block innate immune defenses.The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients.Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis modelProtective Efficacy and Mechanism of Passive Immunization with Polyclonal Antibodies in a Sepsis Model of Staphylococcus aureus Infection.A Neonatal Murine Model of MRSA Pneumonia.Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection.Community-associated meticillin-resistant Staphylococcus aureusGenetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia.Evaluation of humoral immunity and protective efficacy of biofilm producing Staphylococcus aureus bacterin-toxoid prepared from a bovine mastitis isolate in rabbit.Human immune proteome in experimental colonization with Staphylococcus aureus.Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.Staphylococcus aureus adaptation to the host and persistence: role of loss of capsular polysaccharide expression.Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines.The cell surface proteome of Staphylococcus aureus.Immunity against Staphylococcus aureus cutaneous infections.
P2860
Q21131308-252CFBA2-27CA-4AD1-9AB6-AEDE1E53FF01Q27006715-A54396F3-4C92-40BD-90BB-70D4DF58D484Q27007529-125A66FB-1955-43BE-91D9-45E2AF69BF5CQ28478213-9AA5104C-187A-4B76-BDAC-A65DA9852CDDQ30415990-1055E5FD-664B-4B06-BD16-BE8C25EF482EQ33429774-BF1B400C-87F2-4AAF-9127-5574C41E9B09Q33666289-062B93B3-1F91-49A4-922F-F7BDDBECBA99Q33708495-94A360CF-493C-4584-A97F-FFCA2FFA7E39Q33719201-59D01458-5535-45E0-A195-0F5DCB62CA56Q33958347-96EE6333-E2F4-43AA-9D41-1E20379F3E3DQ33970752-3699A4D4-D074-40A2-B2EE-99E750891CABQ34056748-705E8346-AABB-4F5F-9363-370CF068DB7AQ34112608-B05DA260-156A-4224-AB08-9D28117BF3A6Q34113328-286C95EF-E600-4168-B77A-3A5AB3DC50C4Q34484474-F9808B1C-FDBB-42FE-B3F4-9367C57C7FF5Q34522708-0CCDD9A6-B16F-4B75-B1C9-3F79AB30F07BQ34639298-3C4CF5BC-DCC8-4634-973A-E70D438AED5DQ34889865-7C0CDF97-D34C-41E1-92A3-410BD411EA12Q34931562-E6E3CF11-B327-4280-B340-D11836D6B931Q34955442-4E152402-DFAC-4350-839E-28FE35E0E4C5Q34999275-00432265-D8EB-4B75-8812-C907EA5564A5Q35035639-44EF8EB5-A974-4A42-9110-06397CE730B3Q35069186-9AC6D2E5-4B7C-4F52-A91C-EF8CC3050228Q35762600-EC674E41-9854-48D8-A77F-E3AFBFC146D0Q35765208-D14C60B5-C44D-415A-9E4D-FD0CC8F8610FQ35976060-BF317543-AC57-499C-9A23-BD3EACE9B374Q36020705-012F636B-E8F8-45B2-AD6C-E08A19BB9A49Q36184397-25979F41-7D78-4DF0-B978-A00DF1892B90Q36188542-B97DD784-F3E8-4742-B032-BACB196979C3Q36242651-FF5A4FF0-E5D9-4B19-8A81-E2C6D4055EB1Q36368669-93942117-C3E3-4C44-A05D-9AFFF4DBC570Q36438720-B4BB70F9-16D0-431B-8EEA-CC42FEAEC076Q36666780-ACA0E6BE-0E2F-42E1-8D68-39CD30B67171Q36680357-A4630325-AD51-458B-A6E7-3F6E07E34E6BQ37410029-43C7AC81-5657-4D56-8152-7B516A308CF3Q37548140-F07A2C02-8FFE-47CA-8EEA-0392565C7530Q37820667-CC63E563-3B94-4D5D-B2C1-9CD7B4060E12Q37878489-464EC24A-FCE2-4547-8EA8-5AAB9CE40A53Q37883257-E99C5709-488D-4DF7-BF43-C96B4B5C66D8Q37896454-270C41E4-F062-4D06-8420-0A3B725D915B
P2860
Vaccination and passive immunisation against Staphylococcus aureus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccination and passive immunisation against Staphylococcus aureus.
@en
Vaccination and passive immunisation against Staphylococcus aureus.
@nl
type
label
Vaccination and passive immunisation against Staphylococcus aureus.
@en
Vaccination and passive immunisation against Staphylococcus aureus.
@nl
prefLabel
Vaccination and passive immunisation against Staphylococcus aureus.
@en
Vaccination and passive immunisation against Staphylococcus aureus.
@nl
P1476
Vaccination and passive immunisation against Staphylococcus aureus
@en
P2093
Adam C Schaffer
P356
10.1016/J.IJANTIMICAG.2008.06.009
P478
32 Suppl 1
P50
P577
2008-08-30T00:00:00Z